Journal: bioRxiv

Article Title: Granulin loss and TMEM106B risk converge on lysosomal C-terminal fragment pathology in frontotemporal dementia

doi: 10.64898/2026.03.25.713523

Figure Lengend Snippet: A. Western blots show that GRN knockout (KO) in iNeurons leads to accumulation of TMEM106B C-terminal fragments (CTFs) in lysosomes. Purified lysosomes (LysoIP; top) and whole cell lysates (bottom) were from GRN wild type (WT) iNeurons without LysoTag (C-terminally tagged TMEM192-3xHA), GRN WT iNeurons with LysoTag, and GRN KO iNeurons with LysoTag. Lysosomes were purified by immunoprecipitation using the LysoTag. B. Quantification of TMEM106B dimers, monomers, and CTFs from panel A. Normalized ratios were calculated by dividing the intensity of each TMEM106B species (dimer, monomer, or CTF) by the loading control (Beta-tubulin for whole cell lysates; LAMP1 for purified lysosomes), then normalizing to the first bar (WT with LysoTag for purified lysosomes or WT without LysoTag for whole cell lysates). C. qRT-PCR analysis shows that GRN KO does not alter TMEM106B mRNA levels in iNeurons. D. Western blots show that Grn KO in mice leads to accumulation of Tmem106b CTFs in lysosomes. Purified lysosomes were from livers of 6-month-old Grn WT mice without LysoTag, Grn WT mice with LysoTag, and Grn KO mice with LysoTag. Lysosomes were purified by immunoprecipitation using the LysoTag. E. Quantification of Tmem106b dimers and CTFs from panel D. Normalized ratios were calculated by dividing the intensity of each Tmem106b species (dimer or CTF) by the loading control (LAMP1), then normalizing to that of Grn WT with LysoTag. Bar plots represent the mean, and each dot represents a replicate (n = 3-4 replicates per condition). Statistical significance was determined by a two-sided Welch’s t-test: ns (not significant), p > 0.05; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001.

Article Snippet: Primary antibodies used in this work with dilution information are as follows: TMEM106B (E7H7Z) antibody (1:500; Cell Signaling Technology, 93334), cleaved TMEM106B (Ser120) antibody (1:500; Cell Signaling Technology, 87145), C-terminal TMEM106B antibody (1:1000, created in the Dr. Leonard Petrucelli laboratory), GAPDH (1:2000; Sigma-Aldrich, G8795), Histone H3 antibody (1:5000; Abcam, ab1791), Beta-tubulin antibody (1:40000, Sigma-Aldrich, 66240-1-Ig), Human LAMP1 antibody (1:1000, Cell Signaling Technology, 9091P or 15665S), Mouse LAMP1 antibody (1:1000, DSHB, 1D4B), progranulin antibody (1:1000, R&D Systems, AF2420), CTS B (1:1000, Cell Signaling Technology, 31718T), PDI antibody (1:1000, Enzo Life Sciences, ADI-SPA-891-D), Citrate synthase antibody (1:1000, Cell Signaling Technology, 14309T), Golgin-97 antibody (1:1000, Cell Signaling Technology, 13192T), HA-Tag (C29F4) antibody (1:1000, Cell Signaling Technology, 3724S), Catalase antibody (1:1000, Cell Signaling Technology, D4P7B), GFP antibody (1:2000, Antibodies Incorporated, 75-131), and V5 antibody (1:1000, Thermo Fisher Scientific, R960-25).

Techniques: Western Blot, Knock-Out, Purification, Immunoprecipitation, Control, Quantitative RT-PCR

Journal: bioRxiv

Article Title: Granulin loss and TMEM106B risk converge on lysosomal C-terminal fragment pathology in frontotemporal dementia

doi: 10.64898/2026.03.25.713523

Figure Lengend Snippet: A. Left panel: Schematic of TMEM106B showing the T185S coding variant (rs3173615) located in the C-terminal domain. Right panel: Isogenic iPSC-derived neurons were generated with three genotypes: CC (homozygous threonine, TT), CG (heterozygous threonine/serine, TS), and GG (homozygous serine, SS). B. Western blots show that the copy number of the protective S185 allele anti-correlates with TMEM106B CTF levels in the lysosome. Purified lysosomes were from GRN WT iNeurons with TT, TS, or SS genotypes. Lysosomes were purified by immunoprecipitation using the LysoTag. C. Quantification of TMEM106B dimers, monomers, and CTFs from panel B. Normalized ratios were calculated by dividing the intensity of each TMEM106B species (dimer, monomer, or CTF) by the loading control (LAMP1), then normalizing to the first bar (TT genotype) of each TMEM106B species. D. Western blots show that GRN KO increases TMEM106B CTF levels in iNeurons with SS or TT genotypes. Whole cell lysates were analyzed. E. Quantification of TMEM106B CTFs from panel D. Normalized ratios were calculated by dividing the intensity of TMEM106B CTF by the loading control (beta-tubulin) and then normalizing to the first bar. F. Western blots show that recombinant progranulin treatment reduces TMEM106B CTF accumulation in iNeurons with SS, TS, or TT genotypes in a dose-dependent manner. Cells were treated with recombinant progranulin for three days before harvest. G. Quantification of TMEM106B dimers and CTFs from panel F. Normalized ratios were calculated by dividing the intensity of each TMEM106B species (dimer or CTF) by the loading control (beta-tubulin), then normalizing to the first bar (0 nM progranulin) of each genotype group. Bar plots represent the mean, and each dot represents a replicate (n = 3 replicates per condition). Statistical significance was determined by two-sided Welch’s t-test: ns (not significant), p > 0.05; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001.

Article Snippet: Primary antibodies used in this work with dilution information are as follows: TMEM106B (E7H7Z) antibody (1:500; Cell Signaling Technology, 93334), cleaved TMEM106B (Ser120) antibody (1:500; Cell Signaling Technology, 87145), C-terminal TMEM106B antibody (1:1000, created in the Dr. Leonard Petrucelli laboratory), GAPDH (1:2000; Sigma-Aldrich, G8795), Histone H3 antibody (1:5000; Abcam, ab1791), Beta-tubulin antibody (1:40000, Sigma-Aldrich, 66240-1-Ig), Human LAMP1 antibody (1:1000, Cell Signaling Technology, 9091P or 15665S), Mouse LAMP1 antibody (1:1000, DSHB, 1D4B), progranulin antibody (1:1000, R&D Systems, AF2420), CTS B (1:1000, Cell Signaling Technology, 31718T), PDI antibody (1:1000, Enzo Life Sciences, ADI-SPA-891-D), Citrate synthase antibody (1:1000, Cell Signaling Technology, 14309T), Golgin-97 antibody (1:1000, Cell Signaling Technology, 13192T), HA-Tag (C29F4) antibody (1:1000, Cell Signaling Technology, 3724S), Catalase antibody (1:1000, Cell Signaling Technology, D4P7B), GFP antibody (1:2000, Antibodies Incorporated, 75-131), and V5 antibody (1:1000, Thermo Fisher Scientific, R960-25).

Techniques: Variant Assay, Derivative Assay, Generated, Western Blot, Purification, Immunoprecipitation, Control, Recombinant

Journal: Veterinary microbiology

Article Title: Establishment of caprine airway epithelial cells grown in an air-liquid interface system to study caprine respiratory viruses and bacteria.

doi: 10.1016/j.vetmic.2021.109067

Figure Lengend Snippet: Fig. 1. Establishment of well-differentiated caprine airway epithelial cell (AEC) cultures. Immunofluorescence (A) and scanning electron micrographs (B) of well-differentiated caprine AEC cultures. (A) blue: DAPI, grey: ZO-1, red: β-Tubulin IV. Scale bars: 50 μm. The images present a representative selection of data from three different donors. (B) The micrograph illustrates the cilia at the apical surface of the caprine AEC culture. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).

Article Snippet: Cilia were visualized using Alexa Fluor® 647-conjugated rabbit anti-β-tubulin antibody (1:200, Cell Signaling Technology®).

Techniques: Immunofluorescence, Selection

Journal: Veterinary microbiology

Article Title: Establishment of caprine airway epithelial cells grown in an air-liquid interface system to study caprine respiratory viruses and bacteria.

doi: 10.1016/j.vetmic.2021.109067

Figure Lengend Snippet: Fig. 2. Susceptibility and cell tropism of influenza D virus (IDV) on caprine epithelial cell cultures. Caprine AEC were apically infected with 10,000 TCID50 of IDV (A) and mock-infected cells served as a control (B). After 96 h, the cell cultures were fixed and immunofluorescence-stained. The pictures were merged to determine cell tropism and reveal IDV having an affinity to ciliated cells. Grey: ZO-1, red: β-Tubulin IV of ciliated cells, yellow: NP-Protein of IDV. The micrographs present a representative set of data generated from three independent donors. Scale bar: 50 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).

Article Snippet: Cilia were visualized using Alexa Fluor® 647-conjugated rabbit anti-β-tubulin antibody (1:200, Cell Signaling Technology®).

Techniques: Virus, Infection, Control, Immunofluorescence, Staining, Generated

Journal: Neurology Research International

Article Title: Subarachnoid Transplant of the Human Neuronal hNT2.19 Serotonergic Cell Line Attenuates Behavioral Hypersensitivity without Affecting Motor Dysfunction after Severe Contusive Spinal Cord Injury

doi: 10.1155/2011/891605

Figure Lengend Snippet: Neural and human markers with differentiation of the hNT2.19 cell line in vitro. The hNT2.19 cell line was treated for two weeks with retinoic acid and mitotic inhibitors and lifted to substrate-coated 8-well plastic TC slides for differentiation and immunohistochemistry for neuron-specific markers. As soon as 4 days in vitro, a variety of neural markers appeared, which remained strong until at least 6 wks of differentiation: TuJ1 (a), hNSE (b), NFL (c), NFM (d), and NFH (e). For comparison, the negative control hNT2.6 cell line was cultured similarly as the hNT2.19 cells and is here stained for TuJ1 (f). Magnification bar = 20 nm, (a–f).

Article Snippet: For immunohistochemistry of sectioned spinal cord tissues, the polyclonal antibody anti-5HT (ab10385; dilution 1/100 (in vivo)) was purchased from Abcam Inc, Cambridge, MA, and the antihuman TuJ1 antibody (Neuron-specific class III beta-tubulin) was purchased from Neuromics, Edina, MN (MO15013; dilution 1/100 (in vivo).

Techniques: In Vitro, Immunohistochemistry, Comparison, Negative Control, Cell Culture, Staining

Journal: Neurology Research International

Article Title: Subarachnoid Transplant of the Human Neuronal hNT2.19 Serotonergic Cell Line Attenuates Behavioral Hypersensitivity without Affecting Motor Dysfunction after Severe Contusive Spinal Cord Injury

doi: 10.1155/2011/891605

Figure Lengend Snippet: Transplant of hNT2.19 and hNT2.6 cell lines in the severe contusive SCI model: TuJ1 and 5HT immunohistochemistry. Rats were injured with severe contusive SCI followed at two weeks by hNT2.6 (a, b) or hNT2.19 (c, d) cell grafts. Sagittal spinal cord sections were examined at 8 wks after SCI for evidence of surviving lumbar subarachnoid hNT2.6 (a, b) or hNT2.19 (c, d) cell line grafts, utilizing TuJ1 (a, c) or 5HT (b, d) immunohistochemistry. The hNT2.19 and control hNT2.6 (10 6 cells/injection), which had been differentiated for two weeks in vitro, were injected into the subarachnoid space two weeks after the SCI. Cell graft sites were colocalized with 5HT (b, d) and the human-specific marker TUJ1 (neuron-specific class III β -tubulin; (a, c)). There are many surviving hNT2.19 (c) and hNT2.6 (a) grafted cells visible on the pial surface, which stain for TuJ1 (arrows) at the end of the experiment, 56 days after SCI and about 6 weeks after cell transplant. Adjacent sections with the same grafted hNT2.19 (d) and hNT2.6 cells (b) are stained for 5HT, but only the hNT2.19 cells (d) are labeled for 5HT (arrows).

Article Snippet: For immunohistochemistry of sectioned spinal cord tissues, the polyclonal antibody anti-5HT (ab10385; dilution 1/100 (in vivo)) was purchased from Abcam Inc, Cambridge, MA, and the antihuman TuJ1 antibody (Neuron-specific class III beta-tubulin) was purchased from Neuromics, Edina, MN (MO15013; dilution 1/100 (in vivo).

Techniques: Immunohistochemistry, Control, Injection, In Vitro, Marker, Staining, Labeling